Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy

por Hicks, R.J.
Publicado 2010

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with (177)Lu DOTATATE (LuTate)

por Alipour, R., Jackson, P., Bressel, M., Hogg, A., Callahan, J., Hicks, R. J., Kong, G.
Publicado 2023

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial

por Loi, S, Ngan, S Y K, Hicks, R J, Mukesh, B, Mitchell, P, Michael, M, Zalcberg, J, Leong, T, Lim-Joon, D, Mackay, J, Rischin, D
Publicado 2005

FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy

por Day, F L, Link, E, Ngan, S, Leong, T, Moodie, K, Lynch, C, Michael, M, Winton, E de, Hogg, A, Hicks, R J, Heriot, A
Publicado 2011

The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer

por Winton, E de, Heriot, A G, Ng, M, Hicks, R J, Hogg, A, Milner, A, Leong, T, Fay, M, MacKay, J, Drummond, E, Ngan, S Y
Publicado 2009

Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy

por Cheah, C Y, Hofman, M S, Dickinson, M, Wirth, A, Westerman, D, Harrison, S J, Burbury, K, Wolf, M, Januszewicz, H, Herbert, K, Prince, H M, Carney, D A, Ritchie, D S, Hicks, R J, Seymour, J F
Publicado 2013

Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [(18)F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors ver...

por Lopci, E., Hicks, R. J., Dimitrakopoulou-Strauss, A., Dercle, L., Iravani, A., Seban, R. D., Sachpekidis, C., Humbert, O., Gheysens, O., Glaudemans, A. W. J. M., Weber, W., Wahl, R. L., Scott, A. M., Pandit-Taskar, N., Aide, N.
Publicado 2022

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [(18)F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors

por Lopci, E., Aide, N., Dimitrakopoulou-Strauss, A., Dercle, L., Iravani, A., Seban, R. D., Sachpekidis, C., Humbert, O., Gheysens, O., Glaudemans, A. W. J. M., Weber, W. A., Van den Abbeele, A. D., Wahl, R. L., Scott, A. M., Pandit-Taskar, N., Hicks, R. J.
Publicado 2022

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma

por Lewin, J, Khamly, K K, Young, R J, Mitchell, C, Hicks, R J, Toner, G C, Ngan, S Y K, Chander, S, Powell, G J, Herschtal, A, Te Marvelde, L, Desai, J, Choong, P F M, Stacker, S A, Achen, M G, Ferris, N, Fox, S, Slavin, J, Thomas, D M
Publicado 2014

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15–19, 2016; Tübingen, Germany

por Bailey, D. L., Pichler, B. J., Gückel, B., Barthel, H., Beer, A. J., Botnar, R., Gillies, R., Goh, V., Gotthardt, M., Hicks, R. J., Lanzenberger, R., la Fougere, C., Lentschig, M., Nekolla, S. G., Niederdraenk, T., Nikolaou, K., Nuyts, J., Olego, D., Riklund, K. Åhlström, Signore, A., Schäfers, M., Sossi, V., Suminski, M., Veit-Haibach, P., Umutlu, L., Wissmeyer, M., Beyer, T.
Publicado 2016